H
Hugo Guevara
Researcher at California Department of Public Health
Publications - 13
Citations - 4918
Hugo Guevara is an academic researcher from California Department of Public Health. The author has contributed to research in topics: Virus & Coronavirus. The author has an hindex of 10, co-authored 13 publications receiving 3805 citations. Previous affiliations of Hugo Guevara include California Health and Human Services Agency.
Papers
More filters
Journal ArticleDOI
Antigenic and Genetic Characteristics of Swine-Origin 2009 A(H1N1) Influenza Viruses Circulating in Humans
Rebecca Garten,C. Todd Davis,Colin A. Russell,Colin A. Russell,Bo Shu,Stephen Lindstrom,Amanda Balish,Wendy Sessions,Xiyan Xu,Eugene Skepner,Varough M. Deyde,Margaret Okomo-Adhiambo,Larisa V. Gubareva,John R. Barnes,Catherine B. Smith,Shannon L. Emery,Michael J. Hillman,Pierre Rivailler,James A. Smagala,Miranda de Graaf,Miranda de Graaf,David F. Burke,Ron A. M. Fouchier,Claudia Pappas,Celia Alpuche-Aranda,Hugo López-Gatell,Hiram Olivera,Irma Lopez,Christopher A. Myers,Dennis J. Faix,Patrick J. Blair,Cindy Yu,Kimberly M. Keene,P. David Dotson,David Boxrud,Anthony R. Sambol,Syed H. Abid,Kirsten St. George,Tammy L. Bannerman,Amanda L. Moore,David J. Stringer,Patricia Blevins,Gail J. Demmler-Harrison,Michele Ginsberg,Paula Kriner,Steve Waterman,Sandra Smole,Hugo Guevara,Edward A. Belongia,Patricia A. Clark,Sara T. Beatrice,Ruben O. Donis,Jacqueline M. Katz,Lyn Finelli,Carolyn B. Bridges,Michael W. Shaw,Daniel B. Jernigan,Timothy M. Uyeki,Derek J. Smith,Derek J. Smith,Derek J. Smith,Alexander Klimov,Nancy J. Cox +62 more
TL;DR: The lack of similarity between the 2009 A(H1N1) virus and its nearest relatives indicates that its gene segments have been circulating undetected for an extended period as mentioned in this paper.
Journal ArticleDOI
CRISPR-Cas12-based detection of SARS-CoV-2.
James Paul Broughton,Xianding Deng,Guixia Yu,Clare L Fasching,Venice Servellita,Jasmeet Singh,Xin Miao,Jessica Streithorst,Andrea Granados,Alicia Sotomayor-Gonzalez,Kelsey C. Zorn,Allan Gopez,Elaine Hsu,Wei Gu,Steve Miller,Chao Yang Pan,Hugo Guevara,Debra A. Wadford,Janice S. Chen,Charles Y. Chiu +19 more
TL;DR: The CRISPR-based DETECTR assay provides a visual and faster alternative to the US Centers for Disease Control and Prevention SARS-CoV-2 real-time RT–PCR assay, with 95% positive predictive agreement and 100% negative predictive agreement.
Journal ArticleDOI
Genomic surveillance reveals multiple introductions of SARS-CoV-2 into Northern California.
Xianding Deng,Wei Gu,Scot Federman,Louis du Plessis,Oliver G. Pybus,Oliver G. Pybus,Nuno R. Faria,Nuno R. Faria,Candace Wang,Guixia Yu,Brian Bushnell,Chao Yang Pan,Hugo Guevara,Alicia Sotomayor-Gonzalez,Kelsey C. Zorn,Allan Gopez,Venice Servellita,Elaine Hsu,Steve Miller,Trevor Bedford,Alexander L. Greninger,Alexander L. Greninger,Pavitra Roychoudhury,Pavitra Roychoudhury,Lea M. Starita,Michael Famulare,Helen Y. Chu,Jay Shendure,Keith R. Jerome,Keith R. Jerome,Catie Anderson,Karthik Gangavarapu,Mark Zeller,Emily Spencer,Kristian G. Andersen,Duncan MacCannell,Clinton R. Paden,Yan Li,Jing Zhang,Suxiang Tong,Gregory L. Armstrong,Scott Morrow,Matthew Willis,Bela T. Matyas,Sundari Mase,Olivia Kasirye,Maggie Park,Godfred Masinde,Curtis Chan,Alexander T. Yu,Shua J. Chai,Shua J. Chai,Elsa Villarino,Brandon Bonin,Debra A. Wadford,Charles Y. Chiu +55 more
TL;DR: The genomic epidemiology of SARS-CoV-2 in Northern California from late January to mid-March 2020 is investigated, using samples from 36 patients spanning nine counties and the Grand Princess cruise ship to support contact tracing, social distancing, and travel restrictions to contain the spread of the virus.
Journal ArticleDOI
Treatment with neuraminidase inhibitors for critically ill patients with influenza A(H1N1)pdm09
Janice K. Louie,Samuel Yang,Meileen Acosta,Cynthia Yen,Michael C. Samuel,Robert Schechter,Hugo Guevara,Timothy M. Uyeki +7 more
TL;DR: NAI treatment of critically ill pH1N1 patients improves survival, while earlier treatment conveyed the most benefit, patients who started treatment up to 5 days after symptom onset also were more likely to survive.
Posted ContentDOI
Rapid Detection of 2019 Novel Coronavirus SARS-CoV-2 Using a CRISPR-based DETECTR Lateral Flow Assay
James Paul Broughton,Xianding Deng,Guixia Yu,Clare L Fasching,Jasmeet Singh,Jessica Streithorst,Andrea Granados,Alicia Sotomayor-Gonzalez,Kelsey C. Zorn,Allan Gopez,Elaine Hsu,Wei Gu,Steven P. Miller,Chao-Yang Pan,Hugo Guevara,Debra A. Wadford,Janice Chen,Charles Y. Chiu +17 more
TL;DR: The development of SARS-CoV-2 DETECTR is reported, a rapid (~30 min), low-cost, and accurate CRISPR-Cas12 based lateral flow assay for detection of SARs-CoVs, and it is demonstrated comparable performance to the US CDC Sars-Cov-2 real-time RT-PCR assay.